The diffuse large B-cell lymphoma – where do we stand now in everyday clinical practice

BACKGROUND: Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregoric, Brigita, Zadnik, Vesna, Jezersek Novakovic, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472942/
https://www.ncbi.nlm.nih.gov/pubmed/23077452
http://dx.doi.org/10.2478/v10019-012-0002-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472942/
https://www.ncbi.nlm.nih.gov/pubmed/23077452
http://dx.doi.org/10.2478/v10019-012-0002-6

Ejemplares similares